LivaNova (NASDAQ:LIVN) Reaches New 12-Month High at $61.60

LivaNova PLC (NASDAQ:LIVN) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $61.60 and last traded at $60.95, with a volume of 322651 shares trading hands. The stock had previously closed at $55.75.

Analyst Upgrades and Downgrades

LIVN has been the topic of several recent analyst reports. Barclays boosted their price objective on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. StockNews.com upgraded LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Robert W. Baird lifted their target price on LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a research note on Thursday, February 22nd. Mizuho restated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Wednesday, March 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $72.00 target price on shares of LivaNova in a research note on Wednesday, March 20th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $64.40.

LivaNova Price Performance

The firm has a market cap of $3.28 billion, a P/E ratio of 174.22 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The company’s 50-day moving average is $54.32 and its two-hundred day moving average is $50.77.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The company had revenue of $310.10 million during the quarter, compared to the consensus estimate of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The firm’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.81 EPS. Sell-side analysts anticipate that LivaNova PLC will post 3.01 EPS for the current fiscal year.

Institutional Trading of LivaNova

Large investors have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new stake in LivaNova in the third quarter valued at approximately $72,000. Picton Mahoney Asset Management acquired a new stake in shares of LivaNova during the 3rd quarter valued at $91,000. Vanguard Personalized Indexing Management LLC bought a new stake in LivaNova during the 3rd quarter worth $217,000. AlphaMark Advisors LLC acquired a new position in LivaNova in the 3rd quarter worth about $244,000. Finally, Jump Financial LLC bought a new position in LivaNova in the third quarter valued at about $273,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.